ArticleInternational journal of cancer2026
Somatic copy number variation as a prognostic marker for recurrence in never-smokers with early-stage lung adenocarcinoma.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gene amplification in the premalignant stages of non-small cell lung cancer development.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Lung cancer in never-smokers has a distinct genomic profile characterized by lower tumor mutational burden, more tumor-promoting mutations, and fewer somatic copy number variations (CNVs) compared to smokers. While CNVs are linked to poor outcomes in advanced-stage cancer, their role in early-stage lung adenocarcinoma remains unclear. In a cohort of 210 treatment-naive never-smokers with early-stage lung adenocarcinoma, hierarchical clustering of CNVs identified three distinct groups: CNV low (n = 86 [41%]), CNV moderate (n = 75 [36%]), and CNV high (n = 49 [23%]). CNV low tumors had minimal CNV burden, CNV moderate tumors exhibited loss of heterozygosity in chromosomes 3, 9, 13, 15, and 18, and CNV high tumors showed genome-wide amplifications and whole-genome doubling. Recurrence occurred in 42 patients (20%), with a significantly lower 5-year cumulative incidence in the CNV low group (14% [95% CI, 7%-25%]) compared to the CNV moderate (31% [95% CI, 18%-44%]) and CNV high group (48% [95% CI, 27%-66%]) (p = .004). Adjusted hazard ratios for recurrence were 2.30 (p = .074) and 2.65 (p = .037) for CNV moderate and CNV high, respectively. These findings suggest CNV status is an independent predictor of recurrence, with CNV low tumors being associated with the most favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.